ERG-1; ERG1; H-ERG; HERG; HERG1; Kv11.1; LQT2; SQT1
The KCNH2 gene is associated with autosomal dominant long QT syndrome (LQTS), type 2 (MedGen UID: 462293), short QT syndrome (SQTS) (MedGen UID: 355891) and Brugada syndrome (BrS) (MedGen UID: 222975).
Order this gene as a single gene test.
Invitae tests that include this gene:
Pathogenic KCNH2 variants and are associated with ~35% of clinical cases of LQTS. They are also a rare cause of SQTS and are associated with an unknown percentage of clinical cases of BrS.
The KCNH2 gene encodes the potassium voltage-gated channel subfamily H (eag-related) member 2. The electrical activity of cardiac muscle is controlled by the movement of potassium, sodium and calcium ions across cardiac muscle cell membranes. Mutations in genes that encode potassium channels are a common cause of inherited cardiac arrhythmias.
The KCNH2 gene is associated with long QT syndrome (LQTS) type 2, short QT syndrome (SQTS), and Brugada syndrome (BrS), which are cardiac arrhythmia conditions that primarily affect the electrical system of the heart.
The abnormal heartbeats in the above arrhythmia conditions can lead to palpitations, dizziness (presyncope), fainting (syncope), seizure-like activity and, in some cases, sudden cardiac arrest/death, including sudden infant death syndrome. Symptoms can present in both children and adults and may be triggered by homeostatic imbalance or the use of certain medications (PMID: 24011539).
The KCNH2 gene encodes the alpha-subunit of the voltage-gated potassium ion channel Kv11.1 (or HERG), which conducts the rapidly-activating delayed rectifier potassium current (IKr) portion of the heartbeat. Defects affecting the function of this ion channel can delay repolarization, causing arrhythmic events. KCNH2-related SQTS and BrS result from gain-of-function variants, while loss-of-function variants cause LQTS (PMID: 19862833).
KCNH2-related LQTS, SQTS, and BrS exhibit autosomal dominant inheritance. This means that an individual with a pathogenic variant has a 50% chance of passing the variant on to their offspring. Carriers are at increased risk of developing KCNH2-related conditions, and it is now possible to identify at-risk relatives who can pursue testing for this specific familial variant.
KCNH2-related LQTS, SQTS, and BrS exhibit reduced penetrance, meaning that not all individuals with a pathogenic variant will develop clinical features of these conditions (PMID: 21185501, 12736279).
Screening and management recommendations include the following:
Review date: March 2018
Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).
Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.
Our analysis detects most intragenic deletions and duplications at single exon resolution. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. If you are requesting the detection of a specific single-exon copy number variation, please contact Client Services before placing your order.
|Gene||Transcript reference||Sequencing analysis||Deletion/Duplication analysis|